Millions of people worldwide are living with chronic spinal cord injuries, with 250,000 to 500,000 new cases each year—most from vehicle crashes or falls. The most severe spinal cord injuries completely paralyze their victims and more than half impair a person’s ability to breathe. Now, a breakthrough study published in Nature Communications has demonstrated, in animal models of chronic injury, that long-term, devastating effects of spinal cord trauma on breathing and limb function may be reversible.
The new study describes a treatment regimen that helps reawaken certain special types of nerve cells that can regenerate extensions, called axons, within the damaged spinal cord. Rats with spinal cords half severed at the second cervical vertebrae (C2) regained complete diaphragm and partial forelimb function on the severed side after treatment. The recuperative effects of the therapy were fully maintained six months after treatment ended.
“For the first time we have permanently restored both breathing and some arm function in a form of high cervical, chronic spinal cord injury-induced paralysis. The complete recovery, especially of breathing, occurs rapidly after a near lifetime of paralysis in a rodent model,” says senior author Jerry Silver, professor of neurosciences at Case Western Reserve University School of Medicine.
The first author on the study was Phillipa Warren, a postdoctoral fellow at CWRU School of Medicine.
The treatment leverages the body’s innate ability to very slowly sprout new axon branches from a sub-population of nerve cells that remain intact below the injury. The activity of these new branches is completely stifled by a family of potently inhibitory molecules called proteoglycans.
Said Silver: “The strategy was to use a simple, one-time injection of an enzyme, chondroitinase, that breaks down the inhibitory proteoglycan molecules. The enzyme was administered, not within the lesion itself, but lower down within the spinal cord where motor nerve cells reside that send axons out to the diaphragm and forearm.”
In animals treated immediately after spinal cord injury, the enzyme only marginally helped restore nerve growth with minimal functional recovery. However, in animals treated long after injury, the therapeutic effects of the enzyme were remarkably better. In as little as one week after treatment in chronically injured rats, new nerve extensions began to restore diaphragm function that had been silent for many months. Seventy percent of rats treated with the enzyme chronically also began to use their forelimbs to move about and explore their environment (compared to only 30 percent of control animals).
“Surprisingly, the technique worked far better at chronic stages than at acute stages after injury,” says Silver. The longer the animals had been paralyzed, the greater were the restorative effects of the enzyme. Silver’s team found that even after an unprecedented year and a half following spinal cord injury, the treatment could recover full activity to rat diaphragms. One week after treatment, 60 percent of the animals had improved diaphragm function. Two weeks later, every rat showed improvement—even though their paralysis had lasted most of their lives.
Interestingly, exposing the rats to brief periods of low oxygen levels, a respiratory therapy known as acute intermittent hypoxia, helped strengthen the growing nerve extensions, providing an added benefit. However, Silver’s team found that when the rats were treated with the enzyme combined with excessive amounts of respiratory therapy, rats developed chaotic activity in their once paralyzed diaphragms. The researchers hypothesized that the potential for highly abnormal activity may be why the body releases inhibitory molecules to prevent functional axon regeneration in the spinal cord. They are now working to optimize the combination therapy to maximize recovery, especially in the forearm and paw.
“Our data illustrate the relative ease with which an essential motor system can regain functionality months to years after severe spinal cord injury,” says Silver. “The treatment regimen in our study is relevant to multiple types of chronic incomplete spinal traumas, and we are hopeful it may also help restore motor function following spinal cord injury in humans.”
Silver, senior author on the new study, collaborated with researchers from the Division of Pulmonary Critical Care and Sleep Medicine at Case Western Reserve School of Medicine, the Department of Pediatrics at Rainbow Babies and Children’s Hospital, and the Spinal Cord and Brain Injury Research Center at the University of Kentucky for this research.